Spark Newswire Spark Newswire
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
News by Category
  • After-Hours Center
  • Analyst Color
  • Analyst Ratings
  • Asia
  • Asset Sales
  • Binary Options
  • Biotech
  • Bonds
  • Broad U.S. Equity ETFs
  • Buybacks
  • Cannabis
  • Commodities
  • Contracts
  • Crowdsourcing
  • Cryptocurrency
  • Currency ETFs
  • Dividends
  • Downgrades
  • Earnings
  • Earnings Beats
  • Earnings Misses
  • Econ #s
  • Economics
  • Education
  • Emerging Market ETFs
  • Emerging Markets
  • Entertainment
  • Entrepreneurship
  • Equities
  • ESG
  • ETFs
  • Eurozone
  • Events
  • Exclusives
  • FDA
  • Federal Reserve
  • Financial Advisors
  • Financing
  • Fintech
  • Forex
  • Futures
  • Gaming
  • General
  • Global
  • Government
  • Guidance
  • Health Care
  • Hedge Funds
  • Hot
  • Initiation
  • Insider Trades
  • Insurance
  • Interview
  • Intraday Update
  • IPOs
  • Large Cap
  • Latin America
  • Legal
  • Long Ideas
  • M&A
  • Macro Economic Events
  • Macro Notification
  • Management
  • Market Summary
  • Market-Moving Exclusives
  • Markets
  • Media
  • Mid Cap
  • Mining
  • Movers
  • Movers & Shakers
  • Mutual Funds
  • New ETFs
  • News
  • Offerings
  • Opinion
  • Options
  • Penny Stocks
  • Personal Finance
  • Politics
  • Pre-Market Outlook
  • Press Releases
  • Previews
  • Price Target
  • Psychedelics
  • Psychology
  • Real Estate
  • Regulations
  • REIT
  • Reiteration
  • Restaurants
  • Retail Sales
  • Reviews
  • Rumors
  • SEC
  • Sector ETFs
  • Short Ideas
  • Short Sellers
  • Signals
  • Small Business
  • Small Cap
  • Small Cap Analysis
  • Small-Cap
  • Social Media
  • SPACE
  • Specialty ETFs
  • Sports
  • Sports Betting
  • Startups
  • Stock Split
  • Success Stories
  • Tech
  • Technicals
  • Termination
  • Top Stories
  • Topics
  • Trading Ideas
  • Travel
  • Treasuries
  • Uncategorized
  • Upgrades
Spark Newswire Spark Newswire
Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.
  • Newswire
  • News
    • Guidance
    • Dividends
    • M&A
    • Buybacks
    • Legal
    • Interviews
    • Management
    • Offerings
    • IPOs
    • Insider Trades
    • Biotech/FDA
    • Tech
  • Markets
    • After Hours
    • Movers
    • ETFs
    • Forex
    • Commodities
    • Options
    • Binary Options
    • Bonds
    • Futures
    • Global Economics
    • Reviews
    • Small-Cap
    • Cryptocurrency
    • Penny Stocks
  • Analysts
    • Analyst Color
    • Analyst Ratings
    • Upgrades
    • Downgrades
  • Earnings
    • Earnings
  • Support & Feedback
  • Registration Options
  • Log In
Spark Newswire Spark Newswire
Filter By Ticker
Search By Date To
Today | Yesterday | This week
Browsing Category

General

General

Group By Ticker
Sort By
Newest | Oldest
Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers
  • News
  • Small Cap
  • Trading Ideas

Axsome’s Depression Candidate Scores FDA Nod, Stock Surges To 52-High

By Vandana Singh
August 19, 8:38 AM
The FDA has approved Axsome Therapeutics Inc’s (NASDAQ:AXSM) Auvelity (dextromethorphan HBr -bupropion HCl) extended-release tablets for major depressive disorder (MDD) in…

AXSM

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • Movers & Shakers
  • News
  • Small Cap

Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate

By Ragothaman Srinivasan
August 19, 7:42 AM
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.

AXSM

Read More
1 minute read
  • General
  • Media
  • News

GM, LG Energy Solution Plan Fourth US Battery Plant In Indiana: Reuters

By Shivani Kumaresan
August 19, 7:39 AM
General Motors Co (NYSE:GM) and LG Energy Solution are planning to establish a fourth U.S. battery cell manufacturing plant in Indiana, Reuters…

GM

Read More
1 minute read
  • Biotech
  • Events
  • General
  • News

SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022

By Bill Haddad
August 19, 6:32 AM
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that data from the

SWTX

Read More
1 minute read
  • Biotech
  • General
  • Health Care
  • Movers
  • News
  • Penny Stocks
  • Trading Ideas

Read Why Aeglea BioTherapeutics Shares Are Skyrocketing Today?

By Vandana Singh
August 19, 6:26 AM
The European Medicines Agency (EMA) has validated Aeglea BioTherapeutics Inc’s (NASDAQ:AGLE) marketing application seeking approval for pegzilarginase for the treatment of…

AGLE

Read More
2 minute read
  • General
  • News
  • Politics
  • Small Cap

Trump Loyalist Pleads Guilty To Fraud, Furthering Legal Woes For Former President

By Shivdeep Dhaliwal
August 19, 12:19 AM
The former chief financial officer of the Trump Organization pleaded guilty to fraud on Thursday in the New York Supreme Court.

DWAC

Read More
2 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Penny Stocks
  • Small Cap

Recap Of Thursday’s Biotech Catalysts – End Of the Day Summary

By Ragothaman Srinivasan
August 18, 6:19 PM
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA)…

AGLE

Read More
1 minute read
  • Biotech
  • FDA
  • General
  • Health Care
  • News
  • Small Cap

FDA Accepts Krystal Biotech’s Filing For Genetic Skin Disorder Candidate Under Priority Review

By Ragothaman Srinivasan
August 18, 5:42 PM
The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ: KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB).

KRYS

Read More
2 minute read
  • After-Hours Center
  • Entertainment
  • General
  • Large Cap
  • Media
  • News
  • Stock Split
  • Topics
  • Trading Ideas

Why Tesla Stock Will Be More Affordable Next Week

By AJ Fabino
August 18, 5:27 PM
The Elon Musk-led mega-EV company Tesla Inc (NASDAQ: TSLA) announced on Aug. 4 its intention to split its stock just two years after completing another stock split. With the 3-1 split just a week away, here’s what you need to know about it.

TSLA

Read More
1 minute read
  • Analyst Ratings
  • General
  • News
  • Price Target
  • Reiteration

Kohl’s Has ‘Competitive Advantages’ Via Full-Family Offering, Says This Analyst

By Shivani Kumaresan
August 18, 3:32 PM
Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on Kohl’s Corp  (NYSE:KSS) with a price target of $35.00. The analyst…

KSS

Posts pagination

Previous 1 … 2,216 2,217 2,218 … 2,367 Next
Free Newsletter subscribe

Stock Market Ideas & Analysis

Stay up-to-date with the same information professionals use.
Spark Newswire Spark Newswire
  • Newswire
  • Registration
  • Log In
  • Settings
  • Privacy Policy
  • Terms of Service
© 2021 Spark Newswire
All Rights Reserved.

All news is property of their respective owners. Terms of Service